Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza

Biogen has partnered with Alcyone Therapeutics to improve the delivery of its spinal muscular atrophy drug Spinraza, handing over $10 million upfront for a global license to an implantable device.